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Abstract
Prostaglandin F2a (PGF2a), represses ovarian steroidogenesis and initiates parturition in mammals but its impact on adrenal
gland is unknown. Prostaglandins biosynthesis depends on the sequential action of upstream cyclooxygenases (COX) and
terminal synthases but no PGF2a synthases (PGFS) were functionally identified in mammalian cells. In vitro, the most efficient
mammalian PGFS belong to aldo-keto reductase 1B (AKR1B) family. The adrenal gland is a major site of AKR1B expression in
both human (AKR1B1) and mouse (AKR1B3, AKR1B7). Thus, we examined the PGF2a biosynthetic pathway and its functional
impact on both cortical and medullary zones. Both compartments produced PGF2a but expressed different biosynthetic
isozymes. In chromaffin cells, PGF2a secretion appeared constitutive and correlated to continuous expression of COX1 and
AKR1B3. In steroidogenic cells, PGF2a secretion was stimulated by adrenocorticotropic hormone (ACTH) and correlated to
ACTH-responsiveness of both COX2 and AKR1B7/B1. The pivotal role of AKR1B7 in ACTH-induced PGF2a release and
functional coupling with COX2 was demonstrated using over- and down-expression in cell lines. PGF2a receptor was only
detected in chromaffin cells, making medulla the primary target of PGF2a action. By comparing PGF2a-responsiveness of
isolated cells and whole adrenal cultures, we demonstrated that PGF2a repressed glucocorticoid secretion by an indirect
mechanism involving a decrease in catecholamine release which in turn decreased adrenal steroidogenesis. PGF2a may be
regarded as a negative autocrine/paracrine regulator within a novel intra-adrenal feedback loop. The coordinated cell-
specific regulation of COX2 and AKR1B7 ensures the generation of this stress-induced corticostatic signal.
Citation: Lambert-Langlais S, Pointud J-C, Lefranc ¸ois-Martinez A-M, Volat F, Manin M, et al. (2009) Aldo Keto Reductase 1B7 and Prostaglandin F2a Are Regulators
of Adrenal Endocrine Functions. PLoS ONE 4(10): e7309. doi:10.1371/journal.pone.0007309
Editor: Adrian Vella, Mayo Clinic College of Medicine, United States of America
Received June 18, 2009; Accepted September 14, 2009; Published October 7, 2009
Copyright:  2009 Lambert-Langlais et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Centre National de la Recherche Scientifique (CNRS), Universite ´ Blaise Pascal and Fondation pour la Recherche
Me ´dicale (FRM). Human adrenal sections were kindly provided by the Cortico et MEdullosurre ´nale: Etude des Tumeurs Endocrines (COMETE) network. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: antoine.martinez@univ-bpclermont.fr.
. These authors contributed equally to this work.
Introduction
The aldose reductases (AKR1Bs) belong to the aldo-keto
reductase (AKR) superfamily that contains more than 114 proteins
expressed in prokaryotes and eukaryotes. This superfamily
performs oxidoreduction of a wide variety of endogenous and
exogenous substrates including aldoses, aliphatic and aromatic
aldehydes and ketones, monosacharides and prostaglandins [1].
Among the 12 members of the AKR1B subfamily, aldose
reductase (AKR1B1 in human and AKR1B3 in mouse) has been
a focus of interest because of its role in the development of
secondary diabetic complications but its physiological functions
remain poorly understood [2].
Aldose reductase deficient mice (Akr1b3
2/2) exhibit a partially
defective urine-concentrating ability [3,4] and renal structural
abnormalities [5]. AKR1B1/B3 is also present in a broad range of
tissues and other physiological functions based on its enzymatic
activities in vitro have been proposed. Notably, AKR1B1/B3 is
thought to be involved in detoxification of harmful cellular
metabolites including 4-hydroxynonenal [6] and isocaproaldehyde
[7]. But this function remains to be demonstrated in vivo since
AKR1B3 deficient mice appeared to be healthy. It is likely that the
detoxification function may be taken over by other AKR1B
subfamily members. Indeed, we and others have identified
AKR1B7 [8,9] and AKR1B8 [10] as two other murine members
of the family and AKR1B10 has been isolated in human small
intestine [11,12].
AKR1B7 presents two interesting characteristics: a tissue-
restricted expression (vas deferens, steroidogenic tissues, small
intestine and adipose tissue) and a tissue-specific hormonal
regulation [13–19]. In the murine adrenal cortex, the Akr1b7
gene is up-regulated at the transcriptional level by ACTH
[20,21,22] and acts as a major reductase for isocaproaldehyde
formed during steroidogenesis [23]. In human adrenocortical cells,
AKR1B1 was proposed to undertake the same function as
AKR1B7 in murine species, based on its hormonal sensitivity
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Madore and colleagues [25] proposed that the bovine 20a-
hydroxysteroid dehydrogenase also known as AKR1B5 had a
prostaglandin F2a synthase (PGFS) activity in the endometrium.
Furthermore, we have established by in vitro studies, that this
property can be extended to other but not all AKR1B enzymes
since AKR1B1, AKR1B3 and AKR1B7 were shown to catalyze
the reduction of prostaglandin H2 (PGH2) into PGF2a whereas
AKR1B8 and AKR1B10 recombinant proteins were devoid of
such activity [26]. Importantly, based on their kinetic parameters,
recombinant AKR1B1, AKR1B3 and AKR1B7 display better
PGFS activities than the putative PGFS that were previously
characterized in mammals.
Prostaglandins are paracrine/autocrine cell mediators sharing a
common precursor, PGH2, which is synthesized from free
arachidonic acid by the cyclooxygenases type 1 (COX1) or type
2 (COX2). COX1 is regarded as a constitutively expressed
enzyme. COX2 on the other hand is undetectable in most tissues
in basal conditions but can be induced by various mitogenic agents
and inflammatory stimuli (for review see [27]). These different
regulations imply that COX1- and COX2-dependent PG
productions will be primarily required for housekeeping functions
and rapid adaptation to various stimuli, respectively. However, the
identity and regulation of downstream enzymes involved in the
selective production of each isotype of prostaglandins remain
largely unknown. PGF2a is the main initiator of labour and
regression of corpus luteum (luteolysis) in most mammals (for
review see [28]). Two of the hallmarks features of luteolysis are the
decrease in progesterone synthesis and programmed luteal cell
death. PGF2a-induced inhibition of progesterone biosynthesis is
mediated by the PGF2a receptor (FP receptor) present in luteal
cells. Although it has a primary role in reproductive function, the
cellular and molecular mechanisms by which PGF2a is produced
in living cells and its role in other steroidogenic tissues remain
largely unknown [29,30]. AKR1Bs with PGFS activity are highly
expressed and for some of them specifically regulated in the
adrenal cortex. We thus decided to explore the capacity of the
adrenal to produce PGF2a and to investigate the effect that this
production has on the endocrine functions of the gland.
Results
Hormonal regulation and differential expression of
AKR1Bs and COX enzymes in adrenal tissue
We first investigated the effect of modulations of the
hypothalamo-pituitary-adrenal (HPA) axis on the capacity of
mouse adrenal glands to synthesise and respond to PGF2a. For
this, whole adrenal protein extracts were submitted to western blot
analysis (Fig. 1A). As expected, the level of StAR protein (an
ACTH-regulated marker of steroidogenic activity) was decreased
under dexamethasone-mediated HPA axis blockade (low plasma
ACTH) and progressively restored 17 h after the injection of
exogenous ACTH. As previously described, the levels of the
ACTH-responsive aldose reductase-like AKR1B7 followed the
same pattern, confirming the efficiency of the hormonal
treatments [31]. By contrast, AKR1B3 and AKR1B8 proteins
were unresponsive to any of the treatments and exhibited
constitutive expressions. Interestingly, the rate-limiting enzymes
of the prostaglandins synthesis pathway, COX1 and COX2, were
both expressed in the adrenals but showed very different hormonal
sensitivity. COX1 was constitutively expressed. By contrast,
COX2 was undetectable in basal condition. It was strongly
stimulated, 2 h after ACTH injection. This stimulation was
transient, as shown by the reduction of COX2 accumulation
17 h after ACTH administration. In contrast, the PGF2a receptor
FP was constitutively expressed in the adrenal. These data suggest
that mouse adrenal glands have the capacity to synthesize PGF2a
in either a constitutive or an ACTH-dependent manner. The
presence of FP indicates that they might be able to respond to this
signal directly.
Expression of AKR1B7, AKR1B1 and COX2 in mouse and
human adrenal glands was then analysed by immunohistochem-
istry (Fig. 1B). AKR1B7 was detected at high levels in the zona
fasciculata of the cortex in basal conditions. This level was
decreased upon dexamethasone treatment. AKR1B7 staining
increased dramatically and expanded throughout the whole cortex
in the presence of ACTH (Fig. 1B). StAR protein had a similar
expression pattern, although it spanned the entire cortex
irrespective of the hormonal status. In contrast, COX2 positive
cells were only found in the adrenal cortex of ACTH-stimulated
mice. In human adrenal sections, AKR1B1 and COX2 were
restricted to the steroidogenic cells of the cortex (StAR-positive
cells) and were absent from the chromaffin cells of the medulla
(tyrosine hydroxylase positive cells) (Fig. 1C).
In order to define which of the adrenal cell types was
responsible for PGF2a production and which cell type could
respond to this signal, we performed western blot experiments with
both steroidogenic cortical and medullary chromaffin cell lines
(Fig. 2). In contrast with whole adrenal protein extracts (ad.), both
FP receptor and COX1 were absent from the murine Y1
adrenocortical cell line (Fig. 2A). In these cells, AKR1B3 and
AKR1B8 were constitutively expressed. Remarkably, COX2 and
AKR1B7 levels showed parallel time-dependent increases upon
forskolin treatment, an activator of cAMP synthesis that stimulates
steroidogenesis and StAR expression. The murine MPC862L
chromaffin cell line was cultured in the absence or in the presence
of dexamethasone in order to mimick the known stimulatory
action of glucocorticoids on catecholamine production. In contrast
with cortical cells, chromaffin MPC862L cells expressed constitu-
tive high levels of FP receptor and COX1 whereas COX2 was
either absent or expressed at very low levels (Fig. 2B). The aldose
reductase AKR1B3 was constitutively expressed in these cells
whereas AKR1B7 and AKR1B8 were undetectable. We con-
firmed the mutually exclusive expression of AKR1B7 (cortical
cells) and FP receptor (chromaffin cells) by western blots analyses
performed on primary cell cultures from dispersed rat adrenals
(Fig. 2C).
Altogether our data demonstrated that there was a coordinated
cell-specific expression of COX2 and AKR1B7/B1 in the
steroidogenic cells of the adrenocortical cortex. This suggested
that this part of the gland had the potential to produce PGF2a
under cAMP/ACTH control.
Functional coupling between COX2 and AKR1B7
In order to assess a functional coupling between COX2 and
AKR1B7, we stably transfected plasmids encoding these two
enzymes into the HEK293 cell line that is known to be devoid of
COX activity [32] (Fig. 3A, B). Expression of COX2 and
AKR1B7 was confirmed by western blotting (Fig. 3A). Amounts
of PGF2a released in the media by HEK293 clones expressing
COX2 alone or both COX2 and AKR1B7 were measured by
ELISA (Fig. 3B). A low basal production of PGF2a was detected in
similar amounts in three independent COX2-expressing clones
while a 5- to 20-fold increase of PGF2a levels was observed in three
independent clones upon stable introduction of AKR1B7
expression vector. Functional coupling for prostaglandin synthesis
is dependent on a membrane association of both the COX and
prostaglandin synthase enzymes [33,34]. We thus analysed
AKR1B7 and PGF2a in Adrenals
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fractionation of Y1 adrenocortical cells in the absence or presence
of forskolin (Fig. 3C). As expected, COX2 was only associated with
heavy and low membranes fractions in both hormonal conditions
and was absent from nuclear extracts or soluble cytosolic fractions.
Importantly, the PGF synthases AKR1B7 and AKR1B3 which
were previously considered as cytosolic enzymes, colocalized with
COX2 in the heavy membranes fraction and to a lesser extent in
the light membranes fractions. Whereas AKR1B3 was constitu-
tively present in these two fractions, AKR1B7 was only observed
in the presence of forskolin (Fig. 3C). Note that AKR1B8 which
was shown to be devoid of PGF synthase activity [26] was found
associated with heavy membranes in all conditions. StAR, a
mitochondrial protein responsive to cAMP was mainly found
associated with the heavy membrane fraction upon forskolin
stimulation. On the other hand, the steroidogenic transcription
factor SF-1, was found in the nuclear fraction. This validated the
subcellular fractionation procedure. Altogether, we concluded that
Figure 1. Hormonal regulation and differential expression of AKR1Bs, COXs and FP receptor proteins in adrenal glands. A,
Differential expression of AKR1Bs, COXs and FP receptor proteins in response to ACTH in mouse adrenal glands. Protein extracts (30 mg/lane) from
pooled adrenal glands (3 to 6 animals per condition) treated with vehicle alone (5 days, control), dexamethasone (5 days, dex) or dexamethasone (5
days) plus ACTH for time ranging from 2 to 17 h (dex ACTH) were subjected to western blot analysis. Molecular weight markers are shown on the
right. COX2 multiple molecular species are a consequence of the heterogeneous glycosylation of the protein (ns, non specific signal). B,
Immunolocalization of AKR1B7, COX2 and StAR in mouse adrenal sections. Sections of adrenal glands from male mice treated 5 days with vehicle
(control), 5 days with dexamethasone (dex) or with dexamethasone plus ACTH for the last 6 h (dex + ACTH) were immunostained with anti-AKR1B7
(L3 antiserum), anti-COX2 and anti-StAR (steroidogenic cell marker) antibodies (B, bar, 100 mm). C, immunolocalization of AKR1B1, COX2, TH and StAR
in human adrenal sections. Sections of normal human adrenal glands were incubated with anti-AKR1B1 (L3 antiserum), anti-COX2, anti-StAR
(steroidogenic cell marker) and anti-tyrosine hydroxylase (TH) (chromaffin cell marker) antibodies (C, bar, 200 mm). A, artery, M, medulla, ZG, zona
glomerulosa, ZF, zona fasciculata, ZR, zona reticularis, C, capsule.
doi:10.1371/journal.pone.0007309.g001
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AKR1B7 that resulted in PGF2a synthesis.
Hormonal sensitivity of PGF2a production in
adrenocortical cells and the role of AKR1B7
We showed that in Y1 adrenocortical cells, COX2 and
AKR1B7 were associated in the same membrane fractions under
hormonal stimulation. We thus asked whether cAMP would
stimulate PGF2a production in a manner dependent on the
presence of AKR1B7. In order to answer this question we used Y1
cells clones stably transfected with an antisense cDNA targeting
AKR1B7 (AS19) or transfected with an empty vector (EV2) [23].
As expected, AKR1B7 was undetectable in the Y1 AS19 clone
(antisense). The control EV2 and the antisense AS19 clones had
similar levels of expression of AKR1B3, AKR1B8 and COX2
either in basal condition or under forskolin stimulation (Fig. 4A).
Both Y1 clones produced similar amounts of PGF2a in basal
conditions (Fig. 4B). Forskolin treatment induced a two-fold
increase in PGF2a release by Y1 EV2 cells whereas PGF2a
production remained at the basal level in the absence of AKR1B7
(Y1 AS19). To confirm that cAMP/ACTH induced an increase in
PGF2a release in a non-immortalized cell culture model, we
analyzed PGF2a production in primary cultures of rat adrenocor-
tical cells. As shown in Fig. 4C, rat adrenocortical cells showed a
transient stimulation of COX2 expression upon ACTH treatment
for 6h. ACTH sensitivity of rAKR1B7 and StAR protein
accumulation was similar to that observed in Y1 cells, whereas
AKR1B4 (the rat ortholog of mouse AKR1B3) was constitutively
expressed. Rat adrenocortical cells produced PGF2a in basal
condition and showed a 2.5-fold induction of PGF2a release upon
ACTH stimulation (Fig. 4D). These experiments demonstrated
that the AKR1B7 enzyme was responsible for the cAMP/ACTH-
stimulated production of PGF2a by steroidogenic adrenocortical
cells.
Role of PGF2a in adrenal endocrine functions
The experiments illustrated in Fig. 2 provided evidence that the
FP receptor was absent from steroidogenic adrenocortical cells
(either immortalized cells or cells directly dispersed from adrenal
cortex). It is thus likely that PGF2a secreted by these cells might act
as a paracrine factor. We have shown that chromaffin cells
constitutively expressed high levels of FP receptor, COX1 and
AKR1B3. Consistent with this, the MPC862L chromaffin cell line
secreted PGF2a into the culture media. This production was
insensitive to glucocorticoids (dexamethasone) (Fig. 5A). Gluco-
corticoids are known stimulators of catecholamine biosynthesis. In
order to investigate a possible role of PGF2a on glucocorticoid-
induced catecholamine release, we looked at the effects of a PGF2a
analogue (cloprostenol) on the dopamine secretion of MPC862L
cells in the absence or presence of dexamethasone (Fig. 5B). As
expected, dexamethasone induced a 2-fold increase in dopamine
release. Interestingly, treatment with cloprostenol (10
27 M) not
only decreased basal dopamine release but also completely
antagonized dexamethasone-induced dopamine secretion. The
same effect was obtained on dopamine secretion with 2.10
26 M
PGF2a (data not shown). These data strongly suggested that PGF2a
was exerting an inhibitory effect on chromaffin cells dopamine
release, through an autocrine/paracrine mechanism. The con-
centration and content of PGF2a in mouse adrenal tissue were
determined by GC-MS (130638 pmol/g tissue and 4566130 fmol
per gland, respectively) and were in a similar range to levels
measured in cell culture systems (Fig. 4–5). When expressed
Figure 2. Differential expression of AKR1Bs, COXs and FP receptor proteins in cell cultures from adrenal cortex and from adrenal
medulla. A, Time-dependent response to 10
25 M forskolin treatment of StAR, AKR1Bs, COXs and FP receptor proteins levels in adrenocortical Y1 cell
line was analyzed by western blot. Whole adrenal protein extract was used as a positive control, (ad.). B, Expression levels of AKR1Bs, COXs and FP
receptor proteins were analyzed by western-blot in the chromaffin MPC862L cell line either untreated (ctrl) or treated with 10
26 M dexamethasone
(dex) for 12 h. These levels were compared to the levels observed in Y1 cells stimulated by 10
25 M forskolin (Fsk) for 6 h (ns, non specific signal). C,F P
receptor expression in primary cell cultures of rat adrenal cortical and medullary cells. AKR1B7 and TH positive signals were used as markers of
steroidogenic and chromaffin identity, respectively. Molecular weights are indicated on the right.
doi:10.1371/journal.pone.0007309.g002
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tration of PGF2a appeared to be in the mM range.
Cell-cell interactions play a crucial role for maintenance of the
homeostasis of adrenal glands (reviewed in [36]). We showed that
FP receptor was not expressed in the steroidogenic cells of the
adrenal cortex (Fig. 2) and indeed PGF2a had no effect on
steroidogenic activity of Y1 cells or rat adrenocortical cells in
primary cultures (data not shown). This suggested that PGF2a
could not directly influence cortical cell activity. We thus
investigated the effect of PGF2a on corticosterone release by
setting-up perifusions of isolated rat adrenals, an experimental
approach which preserves the architecture of the gland. Various
concentrations of PGF2a and of its synthetic analogue, cloproste-
nol were applied during 20 min. Aliquots of the perifused media
were collected every 10 min for determination of corticosterone
concentrations (Fig. 5C). PGF2a and cloprostenol induced a dose-
dependent inhibition of corticosterone release (Fig. 5D). The half-
maximum effective doses (IC50) of PGF2a and cloprostenol were
1.5860.3610
26 M and 2.5160.2610
28 M, respectively. These
doses were in agreement with physiological contents found in the
adrenal tissue. Maximum responses for PGF2a (239.466.6%) and
cloprostenol (23669.3%) were obtained with concentrations of
3610
26 M and 10
27 M, respectively (P,0.001). The negative
effect of PGF2a was restricted to glucocorticoids since we did not
observe any effect on aldosterone production (data not shown).
Altogether these data demonstrated that physiological concentra-
Figure 3. Functional cellular coupling between COX2 and AKR1B7. A, Western blot analysis of six different HEK293 clones stably transfected
with COX2 expression vector in combination with empty vector (COX2, clones 3, 4, 5) or AKR1B7 expression vector (COX2-AKR1B7, clones 3, 7, 14). B,
ELISA quantification of PGF2a in media from stably transfected HEK293 cell clones, expressing COX2 alone (COX2-3, -4, -5) or in combination with
AKR1B7 (COX2-AKR1B7-3, -7, -14). Cells were stimulated for 30 min with 10 mM A23187 ionophore and culture media were used for PGF2a
quantification. Values were expressed as the mean of 4 experiments 6 S.D. Asterisks point values significantly different from the release of PGF2a by
the COX2-4 cell clone. *, P,0.05, **, P,0.01. C, Subcellular localization of AKR1B7, AKR1B3, AKR1B8 and COX2 in Y1 adrenocortical cells was analysed
by western-blot. Protein extracts (40 mg/lane) from nuclear (Nuc), heavy membrane (HM), light membrane (LM) and cytosolic fractions (Cyt) of Y1
adrenocortical cells untreated or treated with 10
25 M forskolin for 6 h were subjected to western blot analysis. StAR and SF1 signals were used as
markers of heavy membrane fraction and nuclear fraction respectively. Molecular weight markers are shown on the right.
doi:10.1371/journal.pone.0007309.g003
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functions of adrenal glands by inhibiting both catecholamine and
corticosterone release.
Discussion
PGF2a has been shown to be an essential autocrine/paracrine
regulator of ovarian steroidogenesis that initiates luteolysis and
parturition in mammals (reviewed in [28]). Recently, PGF2a was
proposed to exert a repressive effect on testosterone release by
testis Leydig cells [37,38]. Although PGF2a has this prominent role
in the reproductive function, nothing was known about its possible
impact on the adrenal gland. Furthermore, little was known about
the biosynthetic enzymes involved in its selective production
[29,30]. In our previous work, we demonstrated that some aldo-
keto reductase 1B (AKR1B) subfamily members expressed in the
adrenal gland were endowed with high PGF synthase activity in
vitro [26]. Our present work provides new insight in the
understanding of PGF2a biosynthesis and the role of this
prostaglandin in the function of the adrenal gland. Indeed, we
establish for the first time that PGF2a acts as a negative regulator
of adrenal endocrine functions and that the coordinate cell-specific
regulation of both cyclooxygenases (COX1 and COX2) and aldo-
keto reductases of the AKR1B subfamily (AKR1B7, AKR1B1,
AKR1B3) could play a pivotal role in the generation of this signal.
Using in vivo approaches and murine cell culture models, we
have demonstrated that both cortical (steroidogenic cells) and
medullary (chromaffin cells) compartments of the adrenal gland
secreted PGF2a although the isoforms of COX and AKR1B
involved in this biosynthetic pathway differed by their location and
Figure 4. Hormonal sensitivity of PGF2a production in rodent adrenocortical cells and involvement of AKR1B7 protein in PGF2a
production. A, Western-blot analysis of AKR1Bs and COX2 proteins accumulation in stably transfected Y1 cell clones expressing AKR1B7 (empty
vector EV2) or devoid of AKR1B7 (antisense vector AS19) untreated or treated with 10
25 M forskolin (Fsk) for 6 h. Molecular weight markers are
shown on the right. B, ELISA quantification of PGF2a in media from stably transfected Y1 cell clones expressing AKR1B7 (EV2) or devoid of AKR1B7
(AS19), untreated or treated with 10
25 M forskolin for 6 h. C, Differential expression of AKR1Bs and COX2 proteins in primary cultures of rat cortical
cells treated with vehicle (ctrl) or with 10
29 M ACTH for 6 h or 12 h. D, ELISA quantification of PGF2a release in media from rat adrenocortical primary
cells, cultured in the absence or presence of 10
29 M ACTH for 6 h. Values are the mean of 3 experiments 6 S.D. *, P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0007309.g004
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PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7309Figure 5. Role of PGF2a in adrenal endocrine functions. A, ELISA quantification of PGF2a release by chromaffin MPC862L cells untreated
(control) or treated with 10
26 M dexamethasone for 12 h (dex). B, HPLC quantification of dopamine secretion by MPC862L cells cultured in absence
or presence of 10
27 M cloprostenol (clo) (PGF2a analogue) used either alone or in combination with 10
26 M dexamethasone for 12 h (clo+dex).
Values are the mean of 3 experiments 6 S.D. *, P,0.05, ** P,0.01. C, Typical perifusion profiles illustrating the effects of increasing concentrations of
PGF2a (0.1 mMt o1 0mM) and cloprostenol (0.1 nM to 1 mM) on corticosterone secretion. Horizontal bars indicate the start point and duration of PGF2a
or cloprostenol infusions. D, Semi-logarithmic plot showing the effect of increasing concentrations of PGF2a and cloprostenol on the inhibition of
corticosterone secretion. Results are expressed as a percentage of the basal secretory rate. Experimental values were calculated from data similar to
those presented in Fig. 5C. Each curve represents the mean 6 SEM of 6 to 12 independent experiments. After stabilization, the mean secretion rate of
corticosterone in basal condition was 251614 pg/min per adrenal. The concentration-response curve was fitted using the Prism program (GraphPad
Software, Inc., San Diego, CA). **P,0.001.
doi:10.1371/journal.pone.0007309.g005
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expression patterns, PGF2a secretion was found to be modulated
by ACTH in steroidogenic cells and to be constitutive in
chromaffin cells. Indeed, steroidogenic cells only expressed
COX2 and two isoforms of the murine aldose reductases with
patent PGF synthase activity i.e. AKR1B3 and AKR1B7. Among
these enzymes, only COX2 and AKR1B7 were up-regulated by
cAMP/ACTH. In particular, we found that ACTH induced a
rapid (2h) and transient (persisting until 6–7 h and returning to
near control level after 17 h) increase in COX2 protein. By
contrast, chromaffin cells essentially expressed COX1 and
AKR1B3 enzymes in a constitutive manner. Consistent with these
observations, we have demonstrated that the cAMP/ACTH
induction of PGF2a release by steroidogenic cortical Y1 cells,
was strictly dependent on the expression of AKR1B7 and resulted
from a functional cellular coupling with COX2. These experi-
ments provide evidence that AKR1B7 is a bona fide PGF synthase
in vivo. In human, AKR1B1 was previously shown to be
functionally related to the murine AKR1B7 [24]. Here, we
showed that in the normal human adrenal gland, AKR1B1 and
COX2 were co-localized in the steroidogenic cortical cells.
Therefore, it seems likely that the human adrenal cortex could
also have the potential to produce PGF2a in response to ACTH.
However, we observed an unexpected sustained expression of
COX2 on sections of the human adrenal cortex. Although this
might reflect constitutive COX2 expression in the human adrenal
cortex, it seems more likely that this high level of COX2
expression reflects the high stress level of hospitalized patients.
In this respect and in agreement with our results, stress induced by
bacterial lipopolysaccharide injection in rat was shown to trigger a
rapid COX2 mRNA expression in the adrenal cortex [39].
Although both steroidogenic and chromaffin cells of the murine
adrenal gland secreted PGF2a, we showed that FP receptor
expression was restricted to chromaffin cells. Consistent with this
observation, high affinity binding sites for PGF2a were only
detected in the medulla within the bovine adrenal gland [40]. This
suggested that both autocrine (within chromaffin cells) and
paracrine (between steroidogenic and chromaffin cells) mecha-
nisms were relaying PGF2a effects. Our experimental observations
confirm this hypothesis. First, PGF2a had no effect on steroido-
genesis when applied either to isolated murine adrenocortical cell
lines or to rat primary cultures (data not shown) as could be
expected for cells devoid of FP receptor. Second, by contrast,
PGF2a repressed both basal and glucocorticoid-induced catechol-
amine precursor release (dopamine) from a murine chromaffin cell
line. Third, PGF2a was shown to repress corticosterone release in a
dose dependent manner when applied to isolated rat adrenals in
perifusion experiments. Based on these experimental data, we
propose that PGF2a is involved in an intraadrenal regulatory loop
that controls corticosterone release. The cortico-medullary
interactions mediated by PGF2a could be involved in both a
paracrine feedback to limit stress response or in a local control of
basal steroidogenesis. The proposed mechanisms are illustrated in
Fig. 6 and would occur as follows: 1/A stress-induced ACTH
surge triggers a transient induction of COX2 that couples with
AKR1B7 in order to synthesize PGF2a in the steroidogenic
compartment. Increased amounts of PGF2a inhibit glucocorticoid
secretion through an indirect mechanism. This would involve at
least repression of catecholamines release by chromaffin cells.
These are known to promote the secretion of adrenocortical cells
in a paracrine manner [41]. 2/In basal conditions, constitutive
secretion of PGF2a by chromaffin cells exerts an autocrine control
on catecholamines release, thus limiting their paracrine action on
adrenal steroidogenesis. By contrast, PGE2 was shown to promote
the rapid release of glucocorticoid from isolated adrenal glands
upon ACTH stimulation [42]. Hence, our results suggest that in
the adrenal gland as in the female reproductive system [30],
PGF2a/PGE2 exhibit opposite actions with corticostatic/cortico-
trophic and luteolytic/luteotrophic effects, respectively. But
beyond this, our observations highlight an interesting paradox of
PGF2a/PGE2 in fine tuning adrenal endocrine functions. Gluco-
corticoids are potent anti-inflammatory steroids. By inhibiting
glucocorticoids production, adrenal PGF2a limits anti-inflamma-
tory signals, whereas PGE2, a classic pro-inflammatory mediator,
increases anti-inflammatory signals by promoting their secretion
[42]. Hence, the PGF2a/PGE2 paradigm could provide a plausible
Figure 6. Proposed model to illustrate the integrated role of
PGF2a and PGFS of the AKR1B family in adrenal endocrine
functions and cortico-medullary interactions. Free arachidonic
acid (AA) is metabolized into PGH2 by COX enzymes and then
converted into PGF2a by PGFS of the AKR1B family. FP receptor
expression is restricted to the medullary zone. PGF2a synthesized in
both the cortex and medulla thus signals in an autocrine/paracrine
manner on chromaffin cells. This inhibits catecholamines production.
Catecholamines produced in the medulla normally stimulate glucocor-
ticoids release by the cortex. Decreased catecholamine production in
response to PGF2a stimulation thus results in a decrease in glucocor-
ticoids production. The differential expression and regulation of both
COX and AKR1B enzymes within the adrenal zones could allow the
adjustment of PGF2a production to limit stress response or control basal
steroidogenesis by finely tuning glucocorticoid secretion. In basal
conditions, chromaffin cells of the medullary zone constitutively secrete
PGF2a, through the functional coupling between COX1 and possibly the
PGFS AKR1B3. Under stress conditions, the resulting ACTH surge
induces COX2 expression and sustains AKR1B7 levels in the cortex.
Here, we demonstrated that the functional coupling between COX2
and AKR1B7 triggers a PGF2a surge that could act as a local paracrine
feedback to limit catecholamine-mediated glucocorticoid release. After
the stress response has ended, COX2 returns to undetectable levels. The
coupling between AKR1B7 and COX2 does not take place. AKR1B7 then
functions only as a detoxifying enzyme of the harmful aldehydes
produced under chronic/basal stimulation of steroidogenesis [23].
doi:10.1371/journal.pone.0007309.g006
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process [43].
There are few examples of paracrine/autocrine factors that are
involved in a negative control of glucocorticoid production by
acting directly on the adrenal glands. These include the NT1-11
neurotensin fragment [44], urotensin-II (U-II) [45], leptin [46–48]
and the Agouti-related protein (AgRP)[49,50]. Among these
peptides, NT1-11 is not produced by the adrenal and thus acts
as an endocrine factor. By contrast, the three others may be
synthesized within the gland. It is therefore possible that PGF2a-
mediated activation of these repressive peptides could constitute an
alternative (or a complementary) mechanism to PGF2a-mediated
inhibitory tuning of glucocorticoid secretion.
By detoxifying aldehyde by-products of steroidogenesis [23] and
by generating PGF2a that inhibits adrenal steroidogenesis,
AKR1B7 (and possibly AKR1B1 in human) has complementary
actions aimed at protecting the endocrine activity of the adrenal
cortex (Fig. 6). However, because of the two very different kinetic
constants, PGF synthase or isocaproaldehyde reductase activities
are likely to be recruited under different circumstances: the low
affinity for isocaproaldehyde (Km=320 mM) combined to the
highly cAMP/ACTH-dependent expression of AKR1B7 ensures
an efficient reduction of isocaproaldehyde under chronic stimu-
lation of steroidogenesis (high flow of substrate) with a limited risk
of saturation [23]; on the other hand the high affinity for PGH2
(Km=4mM) [26] combined with the acute cAMP/ACTH-
dependent expression of COX2, allows a rapid response to stress.
These two faces of a same enzyme are reminiscent of the 20a-
hydroxysteroid dehydrogenase and PGF synthase activities of the
bovine aldose reductase AKR1B5, that converge to initiate
luteolysis in the bovine endometrium [25].
In summary, we have found that PGF2a exerts a negative effect
on the endocrine functions of both cortical and medullary zones of
the adrenal gland. PGF2a-mediated inhibition of glucocorticoid
production is indirect and could require the downregulation of
catecholamine production. This would then result in downregu-
lation of adrenal steroidogenesis. Alternatively, PGF2a could up-
regulate the expression of inhibitory peptides that remain to be
identified. We provide evidence that this PGF2a signal could
originate from the differential expression and regulation of COX
enzymes and aldo-keto reductases of the AKR1B family.
Materials and Methods
Experimental animals and hormonal manipulations
Animal studies were conducted in agreement with standards
described by the NIH Guide for Care and Use of Laboratory
Animals as well as with the local laws and regulations applicable to
animal manipulations in France. For hormonal regulation studies,
male mice of the B6D2 F1 strain (4-6-months old) were injected sc
with vehicle (sesame oil), dexamethasone acetate for 5 days (75 mg
twice daily; Sigma-Aldrich Corp., St. Louis, MO), or dexameth-
asone acetate (5 d) plus ACTH (10 mg/g, ip; Synacthene, Novartis
Pharma S.A., Rueil-Malmaison, France) for the last 2 h or 17 h.
For immunohistochemistry experiments, male mice were treated
as described above, except for ACTH (1.2 U, im, daily,
Synacthene, Novartis Pharma S.A., Rueil-Malmaison, France)
for the last 6 h.
Rat primary adrenal cells
Wistar male rats (150–200 g) were killed by decapitation.
Adrenals were rapidly removed, and the medulla was separated
from the cortex by squeezing the gland gently after removing the
capsula. Cortical and medullary tissues were then separately
incubated in HBSS for 20 min at 37uC in the presence of
collagenase type I (Invitrogen, Cergy-Pontoise, France). Dispersed
cells were pelleted and the remaining tissues were submitted to 3
or 4 repeated collagenase incubations until digestion was
complete. Supernatants of viable cortical cells were pooled and
seeded at a density of 500,000 cells/well in poly-D-lysine-coated 6-
well plates (Sigma-Aldrich) and maintained at 37uC, 5% CO2 in
Dulbecco’s modified medium (DMEM)/Ham’s F12, for 2 days.
Medium was supplemented with 100 U/ml penicillin and 100 mg/
ml streptomycin, 2.5% fetal calf serum (FCS), 2.5% horse serum
(HS) and 1% insulin-transferrin-sodium selenite (ITS; Sigma-
Aldrich). Dispersed chromaffin cells were pooled and seeded at a
density of 300,000 cells in 6-well plates and maintained in DMEM
for 2 days. Medium was supplemented with 100 U/ml penicillin
and 100 mg/ml streptomycin and 10% FCS. On the third day,
cells were incubated in serum-free medium for 24 hours. Cortical
cells were treated with 10
29 M ACTH (Sigma-Aldrich) for 6 h or
12 h and culture media were removed for PGF2a determination.
Cortical cells and chromaffin cells were collected to perform
western-blot experiments as described below.
HEK293 cell lines expressing COX2 and AKR1B7 by stable
transfection
HEK293 cells were transfected using a COX2 expression
plasmid bearing neomycin resistance kindly provided by Dr M
Murakami (Showas University, Tokyo, Japan) and clones were
selected as previously described [32]. In order to establish cells
transfected with both COX2 and AKR1B7, the clone expressing
COX2 was transfected with the cDNA encoding AKR1B7 cloned
in a pcDNA3.1/hygro vector (Invitrogen) or with the correspond-
ing empty vector using Exgen (Euromedex, Souffelweyersheim,
France). Briefly, 5 mg of plasmid were mixed with 20 mL of Exgen
in 1 mL of 150 mM NaCl and added to cells at 70% confluence in
100 mm culture dishes. After selection in culture medium
supplemented with hygromycin (40 mg/mL) for 4 weeks, single
colonies were picked up and expanded. Expression of COX2 and
AKR1B7 was assessed by western-blotting as described below.
Cell line cultures
Y1 clones stably transfected with empty vector or AKR1B7
antisense cDNA [23] were maintained in DMEM/F12 supple-
mented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin and 200 mg/mL G418 sulfate. For
experiments, Y1 cells (1610
6) were seeded into 6-well plates. The
next day, cells were placed in serum-free medium containing G418
sulfate in the absence or the presence of 10
25 M forskolin (Sigma-
Aldrich) for 30 min to 6 h. MPC862L cells (kindly provided by Dr
J. Powers, Tufts-New England Medical Center, Boston, MA) were
maintained in RPMI 1640 supplemented with 10% HS, 5% FCS,
2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL
streptomycin in dishes with collagen coating [51]. For experi-
ments, MPC862L cells were treated in the same serum-free
medium with or without 10
26 M dexamethasone (Sigma-Aldrich)
or 10
27 M cloprostenol (Sigma-Aldrich) for 12 h. Stable trans-
fected HEK293 cells were maintained in DMEM supplemented
with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, 200 mg/mL G418 sulfate and 20 mg/
mL hygromycin. For cell activation, HEK293 cells (1610
6) were
seeded into 6-well plates. After 2 days, the cells were placed in
antibiotics-free medium supplemented with 1% FCS for 24 h.
Cells were then stimulated for 30 min with 10 mM A23187
ionophore (Calbiochem, Darmstadt, Germany) in the same
medium.
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Y1 cells (6610
7) were scraped gently in PBS-10% glycerol (v/v),
washed in PBS and resuspended in 1 mL of hypotonic buffer
(0.25 M sucrose, 20 mM Tris (pH 7.5), 10 mM KCl, 1.5 mM
MgCl2) containing 1 X protease inhibitor cocktail (Complete,
Roche Diagnostics, Meylan, France), 1 mM NaF and 1 mM
VO4Na3. They were then incubated on ice for 30 min. After
homogeneisation with a Dounce homogenizer (200–300 times), the
lysate was subjected to centrifugation at 800 g for 5 min. The
cytoplasmic supernatant was centrifuged at 10,0006g for 10 min at
4uC to obtain the heavy membrane pellet (HM). The remaining
supernatant was centrifuged at 130,0006g for 1 hour at 4uCt o
obtain the light membrane pellet (LM) and the cytosolic
supernatant. HM and LM fractions were resuspended in 2 volumes
of Triton X-100 lysis buffer (150 mM NaCl, 10 mM Tris pH 7.5,
5 mM EDTA and 1% Triton X-100). Forty mg of total protein from
each fraction were analyzed by western-blotting as described below.
Western-blot experiments
Western-blots were performed as previously described [31].
Blots were incubated overnight at 4uC with the following
antibodies: rabbit anti-COX1 (Cayman, Ann Arbor, MI, 1:500),
rabbit anti-COX2 (Cayman, 1:1000), rabbit anti-FP receptor
(Cayman, 1:500), rabbit anti-StAR (1:5000) [52], rabbit anti-
AKR1B3 (L5, 1:2000), rabbit anti-AKR1B7/B1 (L3, 1:5000),
rabbit anti-AKR1B8 (L7, 1:2000), rabbit anti-Tyrosine Hydrox-
ylase (TH) (Chemicon, Hampshire, UK, 1:10,000), rabbit anti-SF1
(1:2000) [53] or rabbit anti-b-actin (Sigma-Aldrich, 1:3000).
Primary antibodies were detected with a secondary antibody
conjugated to peroxidase (PARIS, Compiegne, France, 1:10,000).
Peroxidase activity was detected with the enhanced chemolumi-
nescent system (ECL, Perkin-Elmer,Courtaboeuf, France). For the
production of antibodies directed against AKR1B isoforms, rabbits
were injected with a glutathione S-transferase fusion of the 17 C-
terminal amino acid residues of the murine AKR1B3, AKR1B7
and AKR1B8 proteins and the antibodies were obtained and
tested as previously described [54]. L7 rabbit antiserum specificity,
was increased by incubation on a GSTrap column (GE
Healthcare, Orsay, France) harbouring the GST-AKR1B7 fusion
protein. L3 antiserum is specific for both murine AKR1B7 and
human AKR1B1, as previously described [24].
Immunohistochemistry experiments
Human adrenal sections were kindly provided by the Cortico et
MEdullosurre ´nale: Etude des Tumeurs Endocrines (COMETE)
network. Adrenal tissue was obtained from normal glands
removed during the surgery of adjacent non-endocrine tumours.
Informed consent was given for adrenal tissue collection as part of
a protocol approved by the Institutional Review Board of the
Cochin Hospital. Mice were killed by vertebral dislocation and
adrenal glands were immediately removed and fixed in Bouin’s
solution at 4uC overnight. After embedding in paraffin, tissues
were sectioned (10 mm) and mounted on slides. Sections were then
deparaffinized in toluene and rehydrated in ethanol with
increasing concentrations of water. Quenching of endogenous
peroxidase activity, incubation with antibodies and peroxidase
staining were performed according to the manufacturer’s instruc-
tions (Vectastain ABC kit and NovaRED substrate kit, Vector
Laboratories, Burlingame, CA). Tissue sections were exposed to
anti-COX2 antibody (Cayman, 1:250), anti-AKR1B7/B1 antise-
rum (L3, 1:500), anti-StAR antiserum (1:500) and anti-TH
antibody (Chemicon, 1:500) at 4uC overnight. Tissues were
counterstained with Harry’s hematoxyline and mounted with
Crystal Mount (Sigma-Aldrich).
Quantification of adrenal PGF2a content
Quantification was performed on pairs of adrenal glands from
nine male mice (4–6 month-old). Individual adrenal weight
was 3.560.6 mg. Deuterated standards (10 ng of d4-PGF2a from
Cayman) were added to homogenized adrenal tissue samples
(2 glands) and acetic acid was added to obtain pH 3. Extraction
was performed three times with 4 ml of ethyl acetate. After each
extraction, the supernatants containing PGs were pooled and
dried under nitrogen. The extracted sample was derivatized into
PG-pentafluobenzylesters and separated by TLC with chloro-
forme/ethanol 93:7 (v/v) as mobile phase. The silica areas
containing PGs derivatives of interest was scrapped off and
extracted three times with 2 mL of ethyl acetate/methanol 4:1
(v/v). An other derivatization was performed to obtain penta-
fluorobenzylester-trimetylsilylether derivatives. Products of
interest were then analyzed by gas chromatography–mass
spectrometry (GC–MS Agilent Technologies). The quantification
was done using selected ion monitoring according to the NICI
mass spectral data obtained with standards. Ions at m/z 569
versus 573 were monitored for unlabeled and deuterated PGs,
respectively.
Analysis of PGF2a release
PGF2a release was measured in 6 h or 12 h culture media.
Cellular debris were removed by centrifugation at 15,0006g and
PGF2a was quantified with a PGF2a ELISA test kit (Neogen,
Lexington, KY) according to the manufacturer’s instructions.
Analysis of catecholamine release
Dopamine release was measured in 12 h culture media of
MPC862L chromaffin line by HPLC analysis with the Chromsys-
tems kit (Mu ¨nchen, Germany).
Perifusion experiments
The effects of PGF2a (Sigma-Aldrich) and cloprostenol (Sigma-
Aldrich) on corticosterone secretion were studied by a perifusion
technique, as described previously [55]. Briefly, slices of rat
adrenal cortex were layered between several beds of Bio-Gel P2
(Bio-Rad Laboratories, Inc., Richmond, CA) into perifusion
chambers (equivalent of two adrenal glands/chamber). Adrenal
tissue was continuously perifused with CO2-saturated HBSS at a
constant flow rate (300 ml/min) and temperature (37uC). The
glands were allowed to stabilize for 5 h to reach a steady-state level
of corticosterone secretion, before any test substance was added.
After stabilization, the mean secretion rate of corticosterone in
basal conditions was 251614 pg/min per adrenal. Test com-
pounds were dissolved in CO2-saturated HBSS immediately
before use and infused into the columns at the same flow rate as
HBSS alone. This was achieved through a multichannel peristaltic
pump (Desaga, Heidelberg, Germany). Effluent fractions were
collected every 5 min (1.5 ml/fraction), and the tubes were
immediately frozen until corticosterone assay. Corticosterone
concentration was determined by RIA, without prior extraction,
in 100 ml aliquots from each fraction. Sensitivity thresholds of the
assays were 20 pg. The intra- and interassay coefficients of
variation were 3 and 6%. Each perifusion pattern was established
as the mean profile of corticosteroid production (6SEM)
calculated from at least six independent experiments. Corticoste-
rone levels were expressed as percentages of the basal values,
calculated as the mean of eight samples (40 min), taken just before
the infusion of test substances. The concentration-response curves
were fitted using the Prism program (GraphPad Software, Inc.,
San Diego, CA).
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For PGF2a and catecholamines quantification in culture media,
statistical analyses were performed by a Student’s t test. Values of
P,0.05 and 0.01 were considered significant and highly
significant, respectively. For corticosterone assay in organ perifu-
sion experiments, statistical significance was assessed by Bonfer-
roni test after one-way ANOVA. Value of P,0.001 was
considered highly significant.
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